Pharmaceutical Executive-08-01-2006

Pharmaceutical Executive

Time Machine

August 01, 2006

Features

0

0

Think you've been around a long time? When's the last time your company gave a doctor a cigarette lighter with your logo on it? Put any corks in medicine bottles lately? Can you remember the last hero shot of a pharma CEO on the cover of Time? We can. And we have the artifacts to prove it...

States Curb Marketing

August 01, 2006

0

0

Pharma restrictions of sales tactics vary from state to state, creating new compliance challenges.

From the Editor: Take Your Seat

August 01, 2006

From the Editor

0

0

The road forward for both public health and the industry is going to require more trust and intimacy, not less, between patients, physicians, FDA, and pharma. Patients need to see a fully functioning set of checks and balances-not what they're seeing today.

Viewpoint: In Your Words

August 01, 2006

0

0

Pharma leaders (and Pharm Exec readers) reflect on the ideas and events that revolutionized the industry over the last quarter of a century--and what to watch for in the next 25.

Quiz Answers

August 01, 2006

0

0

See how well you did on Pharmaceutical Executive's 25th anniversary quiz.

Introduction: Pharm Exec at 25

August 01, 2006

Features

0

0

In 1981, when Pharm Exec published its first issue, the pharmaceutical world was a very different place: There was no direct-to-consumer advertising, no map of the genome, no high-speed screening of millions of compounds. The process of marketing and selling drugs was discreet and nearly invisible to the public; and sales forces, by today's standards, were minuscule. The first biotechs had just launched; and the Bayh-Dole Act, passed the year before, had begun to lay the groundwork for the explosion of research-driven university spin-off companies that transformed the face of research in the 1990s.

How Far We've Come

August 01, 2006

Features

0

0

In 1981, pharma was a more innocent industry. It stood on the brink of an AIDS epidemic that science had yet to name or understand. Hazards of generics, product lifecycles, and off-label marketing lay years ahead. There were no embryonic stem cells to fight over--nor euphemisms like "overactive bladder syndrome" and "erectile dysfunction" to ease conversations or kick off ad campaigns. Who knew what awaited us? To remember--and to reflect on what shaped modern pharma--we invite you to page through the most significant events of the past quarter century.